De novo AML patients with favourable–intermediate karyotype may benefit from the addition of low-dose gemtuzumab ozogamicin (GO) to fludarabine, Ara-C and idarubicin (FLAI): a contribution to the reopened “GO question”
Titel:
De novo AML patients with favourable–intermediate karyotype may benefit from the addition of low-dose gemtuzumab ozogamicin (GO) to fludarabine, Ara-C and idarubicin (FLAI): a contribution to the reopened “GO question”
Auteur:
Clavio, Marino Cruciani, Fabio Minetto, Paola Guolo, Fabio Ballerini, Filippo Marani, Carlo De Astis, Enrico Aquino, Sara Bergamaschi, Micaela Mitscheunig, Laura Grasso, Raffaella Colombo, Nicoletta Ghiggi, Chiara Lovera, Davide Pastori, Giordana Avenoso, Daniele Miglino, Maurizio Gobbi, Marco